Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Conditions: Cystic Fibrosis; Methicillin-resistant Staphylococcus AureusInterventions: Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole; Drug: Minocycline; Drug: Mupirocin; Drug: chlorhexidine gluconate oral rinse; Drug: 2% Chlorhexidine solution wipes; Behavioral: Environmental DecontaminationSponsors: University of North Carolina, Chapel Hill; CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; Washington University School of Medicine; University of Washington; St. Louis Childrens' Hospital; University of Colorado, Denver; Baylor College of Medicine; University of Alabama at Birmingham; Cook Children's Medical Center; University of Michigan; University of Florida; University of Texas Southwestern Medical Center; Children's Hospital Medical Center, CincinnatiActive, not recruiting - verified November 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bactrim | Child Development | Children | Cystic Fibrosis | Environmental Health | Hospitals | Infectious Diseases | Minocycline | MRSA | Mupirocin | Research | Solodyn | Staphylococcus Aureus | Sulfamethoxazole | Superbugs | Trimethoprim